Expedited Review Procedures

Policy

Boston Children’s Hospital permits the review of research protocols through the expedited review process governed by Food and Drug Administration (FDA) and Department of Health and Human Services (DHHS) federal regulations. Protocols that may be reviewed under expedited review are limited to 1) categories of research listed in 45 CFR46.110 if the research involves no more than minimal risk and meet the applicability criteria and 2) minor changes in previously approved research during the period for which approval is authorized. Expedited review procedures may not be used for classified research. The Chair and Vice Chairs of the Institutional Review Board (IRB) are responsible for the final determination as to which protocols, revisions/amendments are eligible for expedited review and each has the authority to designate one or more experienced Committee members to perform the expedited review.

Purpose

The Purpose of this policy is to outline the types of research that may undergo expedited review, and the method used to conduct the expedited review.

Procedures

New

Protocols that may be reviewed under the expedited review process are those listed by the Secretary of DHHS in the Federal Register, 45 CFR46.110(a), and by the FDA in the Federal Register, 21 CFR 56.110(a) (see below). To be eligible for expedited review, all procedures performed for research must be included in the expedited procedure categories, must be considered minimal risk as defined in the regulations and must meet all of the applicability criteria. Classified research is not eligible for expedited review.

All protocols considered for expedited review will undergo and administrative –pre review. The IRB administrative staff will review all protocols for completeness and consistency and provide the investigator with feedback, questions or concerns to be addressed. IRB administrative staff will also provide advice as to what will likely be acceptable within IRB policies and provide input on the protocol and consent document prior to being reviewed. The investigator must respond to the issues raised and changes requested through the pre-review process before protocols are provided to a committee member for expedited review.

Administrators also initially determine whether the protocol meets the criteria for expedited review as specified by the regulations which include the applicability criteria. In addition to meeting one of the categories on the expedited review list, the protocol, in total, must fall under the criteria for minimal risk. It is important to recognize that procedures that may be considered minimal risk in adults may not be minimal risk in children. This may be the result of psychological or emotional distress, even if the actual procedures present minimal
physical risk to the subject. The IRB chair and Vice Chair designate which protocols and
which revisions/amendments may undergo expedited review and may designate any IRB
member as an expedited reviewer or review it themselves.

The standard requirements for informed consent (or its waiver, alteration, or exception)
apply.

After initial screening by the administrative staff of the IRB and the pre-review, the
protocols are brought to the attention of the IRB Chair or Vice Chairs. The Chair or Vice
Chairs will either review the protocol or designate an experienced IRB member to do so. An
experienced IRB member is a member who has served on the IRB for at least 6 months and
has the knowledge and background to be able to conduct the review. In identifying
experienced members who may review protocols, the IRB Chair or Vice Chair will consider
the discipline of the research and length of service and ask the Committee member with
expertise in that discipline to review a particular protocol. Members are asked to declare if
any conflict of interest exists for any protocol they are asked to review through expedited
review procedures. If this is the case it will be reassigned. Any member may be asked to
serve as an expedited reviewer, based on his or her experience, as required and length of
service. If a protocol involves prisoners and is eligible for expedited review, the prisoner
representative will be designated one of the expedited reviewers. The IRB Chair or Vice
Chairs may also refer any protocol to the full Committee for review at a convened meeting.

Even when expedited review is allowed in accordance with federal regulations, the
Chair/Vice Chairs reserve the right to request full Committee review. The Chair’s/Vice
Chair’s determination is final. No member with a conflict of interest may serve as a reviewer
for any expedited item.

The IRB member who conducts the expedited review will be given access to:

i) Protocol smart forms
ii) Experimental Design
iii) Consent/Assent/ Forms
iv) Consent/Assent Waiver and Alteration Information
v) Financial Disclosure and any management plan provided by Compliance review
vi) Investigational Drug Data (as pertinent)
vii) Investigational Device Data (as pertinent)
viii) Request for Clinical Imaging Equipment for Research (as pertinent)
ix) Radiation Exposure and Radioactive Materials (as pertinent)
x) Supplemental Genetic Information (as pertinent)
xi) Pregnant Women and Fetuses information (as pertinent)
xii) Prisoners (as pertinent)
xiii) Recruitment notices, postings, letters
xiv) Complete Department of Health and Human Services (DHHS)-approved
    protocol (if different from above), and any DHHS-approved sample
    consents

In addition to the above items, reviewer will have access to the following:

- A copy of the DHHS grant if funded by DHHS
- Investigational drug/device brochures or other information provided by the sponsor
- Assessments, and questionnaires that are not standard
- Additional reference information
- Copies of the scientific reviewers’ forms and any correspondence related to the
departmental scientific review
All of the criteria specified in 45 CFR 46 are applied as part of the expedited review process. The expedited reviewer is required to complete a worksheet which contains all of the regulatory criteria for approval and include it in the electronic protocol system. Any questions, comments, or requests for revisions (including any that concern the informed consent document) that are received from the reviewer are sent to the investigator in writing through the electronic system. The investigator must respond in writing through the electronic system, and submit any revised forms, protocols, and informed consent documents. The expedited reviewer will indicate whether they want to receive the investigator’s response or whether the administrative IRB staff can verify that the changes have been made. If an investigator is not willing to accept the recommendations and requirements presented as part of the expedited review process, the protocol and the correspondence to date will be placed on the agenda for the next scheduled meeting of the full IRB. Once all issues are resolved and the informed consent finalized, approval will be given.

The designated IRB reviewer may at any time determine that the protocol be forwarded to the full Committee for review. The IRB reviewer may not disapprove an expedited protocol.

A list including the protocol titles, PIs, protocol numbers and designated expedited review categories, is sent to the full Committee at its next scheduled meeting.

**Categories of Research That May Be Reviewed by the IRB through an Expedited Review**

**Applicability**

1. Research activities that
   * present no more than minimal risk to human subjects, and
   * involve only procedures listed in one or more of the following categories, may be reviewed by the IRB through the expedited review process. The activities listed should not be deemed to be of minimal risk simply because they are included on this list. Inclusion on this list merely means that the activity is eligible for review through the expedited review process when the specific circumstances of the proposed research involve no more than minimal risk to human subjects.

2. The categories in the list below apply regardless of the age of subjects, except as noted.

3. The expedited review process may not be used where identification of the subjects and/or their responses would reasonably place them at risk of criminal or civil liability; be damaging to their financial standing, employability, insurability, or reputation; or be stigmatizing, unless reasonable and appropriate protections are implemented so that risks related to invasion of privacy and breach of confidentiality are no greater than minimal.

4. The expedited review process may not be used in classified research that involves human subjects.

5. Categories one (1) through seven (7) pertain to both initial and continuing IRB review.

**Research Categories**

**Category 1**

Clinical studies of drugs and medical devices only when condition (a) or (b) is met.

(a) Research on drugs for which an investigational new drug application (21 CFR Part 312) is not required. Research on marketed drugs that significantly increases the
risks or decreases the acceptability of the risks associated with the use of the product is not eligible for expedited review.

(b) Research on medical devices for which (i) an investigational device exemption application (21 CFR Part 812) is not required; or (ii) the medical device is cleared/approved for marketing and the medical device is being used in accordance with its cleared/approved labeling.

Category 2
Collection of blood samples by finger stick, heel stick, ear stick, or venipuncture, as follows:

- From healthy, nonpregnant adults who weigh at least 110 pounds. For these subjects, the amounts drawn may not exceed 550 ml in an eight week period and collection may not occur more frequently than two times per week; or
- From other adults and children, considering the age, weight, and health of the subjects, the collection procedure, the amount of blood to be collected, and the frequency with which it will be collected. For these subjects, the amount drawn may not exceed the lesser of 50 ml or 3 ml per kg in an eight week period and collection may not occur more frequently than two times per week.

Category 3
Prospective collection of biological specimens for research purposes by noninvasive means.

Examples:
1. Hair and nail clippings in a nondisfiguring manner
2. Deciduous teeth at time of exfoliation or if routine patient care indicates a need for extraction
3. Permanent teeth if routine patient care indicates a need for extraction
4. Excreta and external secretions (including sweat)
5. Uncannulated saliva collected either in an unstimulated fashion or stimulated by chewing gum base or wax, or by applying a dilute citric solution to the tongue
6. Placenta removed at delivery
7. Amniotic fluid obtained at the time of rupture of the membrane prior to or during labor
8. Supra- and subgingival dental plaque and calculus, provided the collection procedure is not more invasive than routine prophylactic scaling of the teeth and the process is accomplished in accordance with accepted prophylactic techniques
9. Mucosal and skin cells collected by buccal scraping or swab, skin swab, or mouth washings
10. Sputum collected after saline mist nebulization

Category 4
Collection of data through noninvasive procedures (that do not involve general anesthesia or sedation) routinely employed in clinical practice, excluding procedures that involve x-rays or microwaves. Where medical devices are employed, they must be cleared/approved for marketing. (Studies intended to evaluate the safety and effectiveness of the medical device are not generally eligible for expedited review, including studies of cleared medical devices for new indications.)

Examples:
1. Physical sensors that are applied either to the surface of the body or at a distance and do not involve input of significant amounts of energy into the subject or an invasion of the subject’s privacy
2. Weighing or testing sensory acuity
3. Magnetic resonance imaging
4. Electrocardiography, electroencephalography, thermography, detection of naturally occurring radioactivity, electroretinography, ultrasound, diagnostic infrared imaging, Doppler blood flow, and echocardiography
5. Moderate exercise, muscular strength testing, body composition assessment, and flexibility testing, where appropriate, given the age, weight, and health of the individual

**Category 5**
Research that involves materials (e.g., data, documents, records, specimens) that have been collected, or will be collected, solely for nonresearch Purposes (e.g., medical treatment, diagnosis).

**Category 6**
Collection of data from voice, video, digital, or image recordings made for research Purposes.

**Category 7**
Research on individual or group characteristics or behavior (including, but not limited to, research on perception, cognition, motivation, identity, language, communication, cultural beliefs or practices, and social behavior), or research that employs survey, interview, oral history, focus group, program evaluation, human factors evaluation, or quality assurance methodologies.

**Category 8**
Continuing review of research previously approved by the convened IRB, as follows:
1. Where
   - the research is permanently closed to the enrollment of new subjects;
   - all subjects have completed all research-related interventions; and
   - the research remains active only for long-term follow-up of subjects; or
2. Where no subjects have been enrolled and no additional risks have been identified; or
3. Where the remaining research activities are limited to data analysis.

**Category 9**
Continuing review of research, not conducted under an investigational new drug application or investigational device exemption, where categories two (2) through eight (8) do not apply but the IRB has determined and documented at a convened meeting that the research involves no greater than minimal risk and no additional risks have been identified.

**Continuing Reviews:**
See the Policy and Procedure for Continuing Review.

**Amendments/Revisions/Modifications**
See the Policy and Procedure “Amendments and Revisions” that discusses the process for expedited review.
Related Content

IRB Policies:

Continuing Review

Amendments and Revisions

Document Attributes

<table>
<thead>
<tr>
<th>Title</th>
<th>Expedited Review Procedures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author</td>
<td>Susan Kornetsky</td>
</tr>
<tr>
<td>Reviewed/Revised by</td>
<td>Susan Kornetsky</td>
</tr>
<tr>
<td>Dates Reviewed/Revised</td>
<td>04/01/05, 06/20/05 03/15/07 05/04/07 03/04/08 03/25/08 05/14/09 03/19/2010 10/29/2010 5/1/15</td>
</tr>
<tr>
<td>Copyright</td>
<td>©Boston Children’s Hospital, 2016</td>
</tr>
<tr>
<td>Last Modified</td>
<td>4/28/16</td>
</tr>
<tr>
<td>Approved</td>
<td>Susan Kornetsky, MPH Director of Clinical Research Compliance August Cervini, MBA Vice President for Research Administration</td>
</tr>
</tbody>
</table>